**7. Future perspectives including economic aspects of genetic test for statin intolerance**

Implementation of a genetic test for statin intolerance into routine practice definitely requires analysing its benefits not only for patients but also for health care providers. In this context, pharmacoecomic data on genetic testing statin intolerance have been scarce. The existing literature on cost-effectiveness of pharmacogenetic testing has been either general [58] or described economic savings solely due to hypolipidemic effect of statins [59]. The first specific data for statin intolerance and its genetic testing appeared only very recently [60]–the authors estimated 356 Canadian dollars as the cost limit for economic feasibility and at the same time dominant health effect for cardiovascular prevention. In extension of this very first report [60], this topic should be, therefore, addressed more intensively and also from other angles in the future. This has been the case with other pharmacogenetic applications (e.g. [61]), it will be also innovative to use new approaches which utilise alternative parameters for assessing effectiveness (e.g. [62–64]).

Though important, inclusion of economic criteria is the only one part of the future priorities in the field of application of genetic variation for testing statin intolerance. Other avenues for future may address (1) further search for and verification of other genetic markers than *SLCO1B1* including providing pharmacokinetic data [65, 66], (2) reflection of ethnic differences in distribution of genetic markers between populations [64, 67], (3) inclusion of the results of genetic test into electronic medical records [68], (4) performing meta-analyses of studies reported so far, and last but not least, (5) performance of well-designed clinical studies implementing also other non-genetic criteria in order to propose a risk-score or clinically applicable algorithm. The existing examples from other pharmacogenetic applications (e.g. [69]) and above described initiatives such as U-PGX [55], RNPGX [56], or the recent idea to provide patients with their DNA (pharmacogenetic) passport [70], allow us to expect further developments targeted at patient benefit and innovation of medical care.

**References**

10.1016/S0140-6736(10)61350-5

10.7326/M16-0838

jacc.2016.12.036

[1] Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;**376**(9753):1670-1681. DOI:

Pharmacogenetics of Cardiovascular Disease: Genetic Variation and Statin Intolerance

http://dx.doi.org/10.5772/intechopen.79518

135

[2] Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes. Annals of Internal Medicine. 2017;**167**(4):221-227. DOI:

[3] Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Canadian Journal of Cardiology. 2016;**32**(7):S35-S65. DOI: 10.1016/j.cjca.2016.01.003 [4] Nissen SE. Statin intolerance: An elusive but morbid disorder. Journal of the American

[5] Serban M-C, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. Journal of the American College of Cardiology. 2017;**69**(11):1386-1395. DOI: 10.1016/j.

[6] Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, De Bacquer D, EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey.

[7] Colantonio LD, Huang L, Monda KL, Bittner V, Serban M-C, Taylor B, Brown TM, Glasser SP, Muntner P, Rosenson RS. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiology.

[8] Yip VLM, Hawcutt DB, Pirmohamed M. Pharmacogenetic markers of drug efficacy and toxicity. Clinical Pharmacology & Therapeutics. 2015;**98**(1):61-70. DOI: 10.1002/cpt.135 [9] Petrek M. Personalized medicine in sarcoidosis. Current Opinion in Pulmonary

[10] Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: Relevance in medical practice: Why drugs work in some patients but not in others. Cleveland Clinic

[11] Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis

Atherosclerosis. 2016;**246**:243-250. DOI: 10.1016/j.atherosclerosis.2016.01.018

Medicine. 2015;**21**(5):532-537. DOI: 10.1097/MCP.0000000000000194

Journal of Medicine. 2011;**78**(4):243-257. DOI: 10.3949/ccjm.78a.10145

2017;**2**(8):890-895. DOI: 10.1001/jamacardio.2017.0911

College of Cardiology. 2017;**69**(11):1396-1398. DOI: 10.1016/j.jacc.2017.01.019
